![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: MFSD9 |
Gene summary for MFSD9 |
![]() |
Gene information | Species | Human | Gene symbol | MFSD9 | Gene ID | 84804 |
Gene name | major facilitator superfamily domain containing 9 | |
Gene Alias | MFSD9 | |
Cytomap | 2q12.1 | |
Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | B4DKY6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84804 | MFSD9 | HCC1_Meng | Human | Liver | HCC | 3.62e-12 | 9.99e-04 | 0.0246 |
84804 | MFSD9 | HCC2_Meng | Human | Liver | HCC | 4.74e-02 | 1.85e-02 | 0.0107 |
84804 | MFSD9 | HCC1 | Human | Liver | HCC | 1.72e-10 | 1.83e+00 | 0.5336 |
84804 | MFSD9 | HCC2 | Human | Liver | HCC | 8.27e-28 | 2.35e+00 | 0.5341 |
84804 | MFSD9 | HCC5 | Human | Liver | HCC | 1.43e-05 | 8.39e-01 | 0.4932 |
84804 | MFSD9 | S014 | Human | Liver | HCC | 1.10e-04 | 2.15e-01 | 0.2254 |
84804 | MFSD9 | S015 | Human | Liver | HCC | 3.32e-09 | 3.93e-01 | 0.2375 |
84804 | MFSD9 | S016 | Human | Liver | HCC | 4.40e-06 | 2.97e-01 | 0.2243 |
84804 | MFSD9 | S028 | Human | Liver | HCC | 8.14e-05 | 2.47e-01 | 0.2503 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MFSD9 | SNV | Missense_Mutation | novel | c.535G>A | p.Gly179Ser | p.G179S | Q8NBP5 | protein_coding | deleterious(0) | probably_damaging(0.983) | TCGA-A8-A0A9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD |
MFSD9 | SNV | Missense_Mutation | c.1305N>C | p.Glu435Asp | p.E435D | Q8NBP5 | protein_coding | deleterious(0) | benign(0.239) | TCGA-AO-A03O-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | |
MFSD9 | SNV | Missense_Mutation | novel | c.91N>A | p.Glu31Lys | p.E31K | Q8NBP5 | protein_coding | tolerated_low_confidence(0.61) | benign(0.042) | TCGA-D8-A1JA-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | PD |
MFSD9 | insertion | Nonsense_Mutation | novel | c.433_434insCTATGTTTAGCACTTAAGAAGCACTCCATGAA | p.Phe145SerfsTer6 | p.F145Sfs*6 | Q8NBP5 | protein_coding | TCGA-A8-A09M-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | paclitaxel | CR | ||
MFSD9 | deletion | Frame_Shift_Del | rs773658597 | c.1326delN | p.Ser443AlafsTer6 | p.S443Afs*6 | Q8NBP5 | protein_coding | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
MFSD9 | insertion | In_Frame_Ins | novel | c.1132_1133insCATTCT | p.Val378delinsAlaPhePhe | p.V378delinsAFF | Q8NBP5 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
MFSD9 | insertion | In_Frame_Ins | novel | c.1131_1132insTCACGCCTGCAAACACAA | p.Val377_Val378insSerArgLeuGlnThrGln | p.V377_V378insSRLQTQ | Q8NBP5 | protein_coding | TCGA-AN-A0FN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
MFSD9 | SNV | Missense_Mutation | novel | c.787N>T | p.Thr263Ser | p.T263S | Q8NBP5 | protein_coding | tolerated(0.45) | benign(0.006) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MFSD9 | SNV | Missense_Mutation | rs753679276 | c.1210N>A | p.Gly404Arg | p.G404R | Q8NBP5 | protein_coding | tolerated(0.08) | possibly_damaging(0.728) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
MFSD9 | SNV | Missense_Mutation | novel | c.613T>G | p.Phe205Val | p.F205V | Q8NBP5 | protein_coding | tolerated(0.16) | benign(0.119) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |